SITC 2017 Abstract Titles – Oncolytic Viruses and Intratumoral Therapies

To search for abstract content based on keywords, select CTRL+F on your keyboard (or Command+F if you're using a Mac) and type a keyword to search for abstracts related to that keyword.







Intratumoral expression of IL12 using the ZVex® dendritic cell-targeting lentiviral vector exerts potent anti-tumor effects via induction of multiple immune effectors, including CD8 T cell responses

Tina C. Albershardt1, Jardin Leleux1, Rebecca S. Reeves1, Jan ter Meulen1, Peter Berglund1

1Immune Design, Seattle, WA, USA

Antigen presenting cells | Dendritic cell | Inflammation | Tumor microenvironment | Targeted therapy | Tumor antigens | Cytokine | Immune adjuvant | Vaccine


Chemotherapy Enhances Oncolytic Recombinant Poliovirus Efficacy

Jeffrey Bryant1, Michael Brown2, Matthias Gromeier2

1Duke University, Durham, NC, USA 2Duke University Medical Center, Durham, NC, USA

Chemotherapy | Regulatory T cell (Treg) | Tumor microenvironment | Tumor infiltrating lymphocytes (TILs) | Tumor antigens | Vaccine | Clinical study | Immune suppression


Intratumoral administration of a multigene construct by electroporation can effectively modulate anti-tumor response in a murine B16.F10 model

Shawna Shirley1, Anandaroop Mukhopadhyay1, Christoph Burkart1, Jocelyn Wright1, Robert Pierce2, Jean Campbell2, David Canton1

1Oncosec Medical Incorporated, San Diego, CA, USA 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Tumor infiltrating lymphocytes (TILs) | T cell | Antigen presenting cells | Neoantigens | Tumor antigens | Cytokine | Gene expression | Dendritic cell | Tumor microenvironment


Targeting T-cells to human cancer associated fibroblasts using an oncolytic virus expressing a FAP-specific T-cell engager

Brian Champion1, Joshua Freedman2, Rebecca Ashfield2, Margaret Duffy2, Alice Brown1, Leonard Seymour2, Kerry Fisher2

1PsiOxus Therapeutics Ltd, Abingdon, United Kingdom 2Oxford University, Oxford, United Kingdom

T cell | Tumor stroma | Tumor microenvironment | Targeted therapy | Solid tumors


Harnessing pre-existing antiviral immunity to treat solid tumors

Nicolas Cuburu1, Rina Kim1, Sergio Pontejo2, Cynthia Thompson1, Douglas Lowy1, John Schiller1, John Schiller3

1National Cancer Institute, NIH, Bethesda, MD, USA 2National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA 3NCI/NIH, Bethesda, MD, USA

Solid tumors | Vaccine | Immune adjuvant | Tumor antigens | Tumor microenvironment | Neoantigens | T cell | Tumor infiltrating lymphocytes (TILs)


Dissecting the mechanisms underlying antitumor effects of live oncolytic vaccinia and heat-inactivated vaccinia.

Weiyi Wang1, Peihong Dai1, Ning Yang1, Stewart Shuman1, Taha Merghoub1, Jedd Wolchok1, Liang Deng1

1Memorial Sloan Kettering Cancer Center, New York, NY, USA

Tumor infiltrating lymphocytes (TILs) | Monocyte/Macrophage | Dendritic cell | Myeloid cells | Antigen presenting cells | Checkpoint blockade


In situ vaccination for cancer immunotherapy: treat locally, respond systemically

Nicole Steinmetz1, P. Jack Hoopes2, Mee Ree Sheen2, Chenkai Mao2, Scott Sieg1, Steven Fiering2, Patrick :Lizotte2, Amy Wen3

1Case Western Reserve University, Cleveland, NH, USA 2Geisel School of Medicine at Dartmouth, Lebanon, NH, USA 3Case Western Reserve University, Cleveland, OH, USA

Tumor microenvironment | Vaccine | Immune adjuvant | Tumor infiltrating lymphocytes (TILs)


Tumor Cell-Intrinsic STING Signaling and Regulation of IFN-β Gene Expression

Blake Flood1, Leticia Corrales2, Thomas Gajewski1

1University of Chicago, Chicago, IL, USA 2Aduro Biotech, Chicago, IL, USA

Inflammation | Cytokine | Gene expression | Immune adjuvant | Tumor evasion


Efficacious anti-melanoma immunity induced by OX40 ligand-expressing oncolytic adenovirus Delta-24-RGDOX

Hong Jiang1, Andrew Dong1, Caroline Carrillo1, Verlene Henry1, Xuejun Fan1, Yisel Rivera-Molina1, Francisco Puerta-Martinez1, Teresa Nguyen1, Karen Clise-Dwyer1, Frederick Lang1, Candelaria Gomez-Manzano1, Juan Fueyo1

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Tumor microenvironment | Checkpoint blockade | Targeted therapy | Antibody | Monocyte/Macrophage | Solid tumors | Vaccine


Generation of therapeutic RNAs to induce immunogenic cell death and interferon expression in cancer cells

Jaewoo Lee1, Youngju Lee2

1Duke University Medical Center, Durham, NC, USA 2Duke University, Durham, NC, USA

Cytokine | Immune adjuvant | Inflammation | TLR | Tumor microenvironment


Immunotherapy with BO-112, a novel double-stranded RNA-based agent, promotes tumor cell death and boosts T cell immunity in preclinical mouse models

Lourdes Planelles1, Angela Aznar2, MªJosé Gómez-Sánchez1, Mercedes Pérez-Olivares1, Saray Garasa2, Mercedes Pozuelo1, Ivan Márquez-Rodas3, Marisol Quintero1, Ignacio Melero2

1BIoncotech Therapeutics, Valencia, Spain 2Center for Applied Medical Research (CIMA) & University of Navarra, Pamplona, Spain 3Hospital General Universitario Gregorio Marañón, Madrid, Spain

TLR | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment


Antitumor immunity in patients with locally advanced soft tissue sarcoma treated with hafnium oxide nanoparticles and radiation therapy

Jérôme Galon1, Marick Laé2, Juliette Thariat3, Sébastien Carrere4, Zsuzsanna Papai5, Martine Delannes6, Philippe Rochaix6, László Mangel7, Fabienne Hermitte8, Zoltán Sapi9, Tamas Tornoczky7, Vincent Servois2, Isabelle Birtwisle Peyrottes3, Raphaël Tetreau4, Marie-Christine Château4, Sébastien Paris10, Hervé Brisse2, Sylvie Bonvalot2

1INSERM, Paris, France 2Institut Curie, Paris, France 3Centre Antoine Lacassagne, Nice, France 4Centre Régional De Lutte Contre Le Cancer Paul Lamarque, Montpellier, France 5Medical Centre, Hungarian Defence Forces, Budapest, Hungary 6Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France 7Pecs University, Pecs, Hungary 8HalioDX, Marseille, France 9Semmelweis University, Budapest, Hungary 10Nanobiotix, Paris, France

Tumor microenvironment | Biomarkers | Radiotherapy | Solid tumors | Tumor infiltrating lymphocytes (TILs)


Transforming immunologically “cold” tumor into “hot” tumor with hafnium oxide nanoparticles and radiation therapy

Sébastien Paris1, Audrey Darmon1, Ping Zhang1, Maxime Bergère1, Laurent Levy1

1Nanobiotix, Paris, France

Tumor microenvironment | Biomarkers | Tumor infiltrating lymphocytes (TILs) | Radiotherapy | Solid tumors


PVSRIPO is an Interferon-Resistant, Immunotherapeutic Oncolytic Virus

Ross Walton1, Michael Brown1, Eda Holl1, David Boczkowski1, Vidya Chandramohan1, Smita Nair1, Matthias Gromeier1

1Duke University, Durham, NC, USA

Antigen presenting cells | Dendritic cell | Inflammation | Cytokine | Immune adjuvant | Solid tumors


Upregulation of PD-L1 in tumor microenvironment is a resistance mechanism for oncolytic virus immunotherapy

Dmitriy Zamarin1, Jacob Ricca1, Anton Oseledchyk1, Mathieu Gigoux1, Taha Merghoub1, Jedd Wolchok1

1Memorial Sloan Kettering Cancer Center, New York, NY, USA

Checkpoint blockade | Tumor microenvironment | Vaccine